US EditionWe Enter the Factory Where Inhalers Are Produced that Reduce Climate Impact
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
In the middle of the Dunkirk industrial area (North), the AstraZeneca plant has become a global pillar of the group's decarbonization strategy. Since the 1990s, the site has been home to the worldwide production of inhaled medicines (dry powders and aerosols) for the treatment of asthma and chronic obstructive bronchopneumopathy (COPD).
Combating climate change is a complex challenge, and improving the treatment of respiratory diseases such as COPD, which affects three million Spaniards, is already an urgent need. However, AstraZeneca has achieved a milestone: an authorized drug for the treatment of chronic obstructive pulmonary disease with a virtually zero Global Warming Potential (GWP). This triple combination therapy at fixed doses has a carbon footprint comparable to that …
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
